痛泻要方加减或联合西药治疗溃疡性结肠炎的系统评价和Meta分析

发布时间：2018-05-03 01:27

本文选题：痛泻要方 + 溃疡性结肠炎　；参考：《时珍国医国药》2017年06期

【摘要】：目的系统分析痛泻要方加减治疗溃疡性结肠炎的临床疗效。方法计算机检索PubMed、EMBASE、中国知网、中国生物医学文献数据库、维普和万方数据库等全文数据库,纳入痛泻要方加减联合西药或单用痛泻要方加减对比单用西药治疗溃疡性结肠炎的随机对照试验(RCTs)文章,用Cochrane评价方法对文章的风险偏倚进行评价;使用RevMan 5.3版本对纳入的文献进行Meta分析。结果共纳入8篇RCTs文献,共计696例患者。Meta分析结果示:对比单用西药,痛泻要方加减联用西药和单用痛泻要方加减疗效的合并RR值分别为RR=1.25,95%CI:(1.10,1.42)和RR=1.22,95%CI:(1.12,1.33),差别均有统计学意义(P0.05)。敏感性分析和漏斗图分析显示纳入的文献同质性较强,不存在发表偏倚。结论对比单用西药,痛泻要方加减或联用西药治疗溃疡性结肠炎有更好的临床疗效。但由于纳入文献的质量不高,在试验设计存在严重不足,需要高质量的大样本双盲随机对照试验的支持。
[Abstract]:Objective to analyze the clinical effect of Tongxieyao decoction in the treatment of ulcerative colitis. Methods the full-text databases of PubMedus EMBASE, China knowledge Network, Chinese Biomedical Literature Database, Weip and Wanfang databases were searched by computer. A randomized controlled trial (RCTs) was used to evaluate the risk bias of the treatment of ulcerative colitis with the addition or subtraction of Tongxieyiefang plus or minus western medicine alone. The risk bias of the article was evaluated by Cochrane evaluation method. Use RevMan version 5.3 to perform Meta analysis of the included literature. Results A total of 696 patients with RCTs were included in this study. The results of meta-analysis showed that the combined RR values of addition and subtraction of Tongxiefangfang plus or minus western medicine and Tongxieyao recipe were RRX 1.2595 CIW 1.101.42 and RR1.2295CIW 1.121.33, respectively. The difference was statistically significant (P < 0.05). Sensitivity analysis and funnel analysis showed that the literature included was homogeneous and there was no publication bias. Conclusion compared with western medicine alone, Tongxie important prescription or combined with western medicine has better clinical effect in the treatment of ulcerative colitis. However, due to the low quality of the literature included, there are serious deficiencies in the experimental design, which requires the support of a large sample of double-blind randomized controlled trials with high quality.
【作者单位】：广州中医药大学第一临床医学院;广州中医药大学第一附属医院;
【基金】：广东省自然科学基金项目广州中医药大学第一附属医院脾胃病重点学科资助项目(No.2016A030313643)
【分类号】：R574.62

【参考文献】